melitten and Glioma

Nanosized lipodisks with flat circular phospholipid bilayers surrounded by PEGylated edges have demonstrated promise in drug delivery. In the present work, a lipodisk-based paclitaxel and melittin co-delivery system functionalized with glycopeptide 9G-A7R (9G-A7R-Disk/PTX/melittin) was successfully constructed, in which melittin which was fully protected from proteolysis and hemolysis was effectively reduced. The ratio of paclitaxel to melittin in lipodisks could be accurately controlled through a film hydration-adsorption method. Paclitaxel combined with melittin showed synergism against U87 cells in vitro, and 9G-A7R-Disk/PTX/melittin demonstrated an enhanced anti-glioma effect in vivo, significantly prolonging the survival time of glioma-bearing mice. The results suggested a promising formulation for the co-delivery of paclitaxel/melittin and glioma-targeted therapy.

Topics: Animals; Brain Neoplasms; Drug Delivery Systems; Female; Glioma; Glycopeptides; Humans; Melitten; Mice; Mice, Nude; Nanoparticles; Paclitaxel; Xenograft Model Antitumor Assays

To investigate the anti-tumor effects of melittin against malignant human glioma cells in vitro.. Two malignant human glioma cell lines (U87 and U251) were treated with melittin at various concentrations, and the cell growth inhibition and apoptosis were evaluated using MTT assay, flow cytometry and agarose gel electrophoresis.. Melittin could obviously inhibit the proliferation of the two glioma cell lines (P<0.05). At the concentrations of 1, 10, 20, 40, 80, 160, 200 mg/L, melittin resulted in U87 cell apoptosis rates of 12.80%, 16.92%, 22.69%, 34.05%, 41.82%, 59.87%, and 80.25%, and in U251 cell apoptosis rate of 11.61%, 16.21%, 22.03%, 30.57%, 41.10%, 58.33%, and 79.12%, respectively, showing a dose-dependent effect in its action of inducing cell apoptosis.. Melittin inhibits the proliferation and induces apoptosis of malignant human glioma cell lines in vitro.

Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Glioma; Humans; Melitten

The cellular cGMP content increased in response to a variety of receptor agonists, which activate [e.g., prostaglandin (PG) E1, E2, and F2 alpha] or inhibit (e.g., alpha-adrenergic, muscarinic, and opiate agonists) adenylate cyclase in neuroblastoma X glioma hybrid NG108-15 cells. The responses were additive when PGF2 alpha and enkephalin were mixed. The inhibitory guanine nucleotide regulatory protein (Ni) is involved in adenylate cyclase inhibition; this function of Ni is lost when it is ADP-ribosylated by islet-activating protein (IAP), pertussis toxin [H. Kurose, T. Katada, T. Amano, and M. Ui (1983) J. Biol. Chem. 258, 4870-4875]. The cGMP rise induced by stimulation of the receptors linked to adenylate cyclase inhibition was also diminished by IAP; the time course and dose response for the IAP-induced diminution were the same between adenylate cyclase inhibition and cGMP generation. Ni thus appears to mediate guanylate cyclase activation as well as adenylate cyclase inhibition initiated via the same receptors. Melittin also increased cGMP. No additivity was shown when enkephalin and melittin were combined, suggesting that phospholipase A2 might play a role in Ni-mediated guanylate cyclase activation. On the other hand, the PGF2 alpha-induced cGMP rise was associated with increased incorporation of 32Pi into phosphatidylinositol; was not affected by cholera toxin, IAP or forskolin; and showed no additivity when combined with A23187, which increased cGMP by itself. PGs would occupy receptors linked to phosphatidylinositol breakdown, thereby increasing the availability of intracellular Ca2+, which is responsible for guanylate cyclase activation. Thus, dual pathways are proposed for a receptor-mediated cGMP rise in NG108-15 cells.

Topics: Adenylate Cyclase Toxin; Animals; Bacterial Toxins; Calcimycin; Cyclic AMP; Cyclic GMP; Dinoprost; Enkephalins; Glioma; Hybrid Cells; Melitten; Mice; Neuroblastoma; Pertussis Toxin; Phospholipids; Prostaglandins F; Rats; Receptors, Cell Surface; Virulence Factors, Bordetella